J&J’s Darzalex Faspro is first US therapy for rare blood disorderJohnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain Share XJ&J’s Darzalex Faspro is first US therapy for rare blood disorderhttps://pharmaphorum.com/news/jjs-darzalex-faspro-is-first-us-therapy-for-rare-blood-disorder/
Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the tableAlexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and Share XAlexion finally has a buyer – and it’s AstraZeneca with $39bn on the tablehttps://pharmaphorum.com/news/alexion-finally-has-a-buyer-and-its-astrazeneca-with-39bn-on-the-table/
Chasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trialAlexion and development partner Caelum Biosciences have begun late-stage trials of their light-chain (AL) amyloidosis drug CAEL-101, snapping Share XChasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trialhttps://pharmaphorum.com/news/chasing-janssen-alexion-and-caelum-start-phase-3-al-amyloidosis-trial/
Roche takes on Alexion as FDA approves satralizumab in NMOSDThe FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the Share XRoche takes on Alexion as FDA approves satralizumab in NMOSDhttps://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/
Alexion trials rare disease drug Ultomiris in severe COVID-19 casesPharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined Share XAlexion trials rare disease drug Ultomiris in severe COVID-19 caseshttps://pharmaphorum.com/news/alexion-trials-rare-disease-drug-ultomiris-in-severe-covid-19-cases/
Roche trumpets data for Soliris rival in NMOSD after US, EU filingsRoche has continued to build the case for satralizumab, its experimental therapy for rare disease neuromyelitis optica spectrum Share XRoche trumpets data for Soliris rival in NMOSD after US, EU filingshttps://pharmaphorum.com/news/roche-trumpets-data-for-soliris-rival-in-nmosd-after-us-eu-filings/
Alexion stalks rare disease drug from Stealth with $30m opt-in dealAlexion has taken an option on a rare disease drug from Stealth Therapeutics in late-stage development, bolstering its Share XAlexion stalks rare disease drug from Stealth with $30m opt-in dealhttps://pharmaphorum.com/news/alexion-stalks-rare-disease-drug-from-stealth-with-30m-opt-in-deal/
UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionUCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage Share XUCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionhttps://pharmaphorum.com/news/ucb-takes-on-rare-diseases-giant-alexion-with-ra-pharma-acquisition/
Roche preps filings for satralizumab in rare disease NMOSDRoche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis Share XRoche preps filings for satralizumab in rare disease NMOSDhttps://pharmaphorum.com/news/roche-preps-filings-for-satralizumab-in-rare-disease-nmosd/
